And we also propose adoption of an ideal gene therapy approach that combines the gene-correction process with the TD process, focusing on the example of the pathogenic LRRK2 mutant (G2019S), which progressively depletes neural stem cells in Parkinson's disease. This evidence concerns the gene LRRK2 and Parkinson disease.